Literature DB >> 17973250

Coexisting somatic promoter hypermethylation and pathogenic MLH1 germline mutation in Lynch syndrome.

N Rahner1, N Friedrichs, V Steinke, S Aretz, W Friedl, R Buettner, E Mangold, P Propping, C Walldorf.   

Abstract

Somatic epimutations in the MLH1 promoter mimic the phenotype of Lynch syndrome. To date, no somatic hypermethylation of the MLH1 promoter in the carrier of a pathogenic MLH1 germline mutation has been identified, prompting the recommendation that a germline mutation in MLH1 should only be sought in the absence of tumour tissue methylation. We aimed to determine whether methylation of the MLH1 promoter may coexist in carriers of a pathogenic germline mutation in MLH1. We examined the methylation status of the MLH1 promoter in 123 tumour tissue samples, demonstrating high microsatellite instability and loss of expression of a mismatch repair protein (60 cases with MLH1 germline mutation, 25 cases without mutation, 38 cases with MSH2 mutations), using combined bisulphite restriction analysis (COBRA) and SNaPshot analysis. Methylation of the MLH1 promoter was found in two patients with pathogenic germline mutations, one a carrier of a MLH1 mutation and the other a carrier of a MSH2 mutation. Our results demonstrate that methylation of the MLH1 promoter region does not exclude the presence of a germline mutation in a mismatch repair (MMR) gene. Hypermethylation of the MLH1 promoter may be present in most cases of sporadic colorectal cancers, but this does not exclude a diagnosis of Lynch syndrome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 17973250     DOI: 10.1002/path.2263

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  20 in total

1.  MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study.

Authors:  Mireia Gausachs; Pilar Mur; Julieta Corral; Marta Pineda; Sara González; Llúcia Benito; Mireia Menéndez; Josep Alfons Espinàs; Joan Brunet; María Dolores Iniesta; Stephen B Gruber; Conxi Lázaro; Ignacio Blanco; Gabriel Capellá
Journal:  Eur J Hum Genet       Date:  2012-01-25       Impact factor: 4.246

2.  [DNA methylation. From basic research to routine diagnostics].

Authors:  U Lehmann
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

3.  High risk for neoplastic transformation of endometriosis in a carrier of Lynch syndrome.

Authors:  Christine Nyiraneza; Etienne Marbaix; Mireille Smets; Christine Galant; Christine Sempoux; Karin Dahan
Journal:  Fam Cancer       Date:  2010-09       Impact factor: 2.375

4.  Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition?

Authors:  Eddy H J van Roon; Marjo van Puijenbroek; Anneke Middeldorp; Ronald van Eijk; Emile J de Meijer; Dianhdra Erasmus; Kim A D Wouters; Manon van Engeland; Jan Oosting; Frederik J Hes; Carli M J Tops; Tom van Wezel; Judith M Boer; Hans Morreau
Journal:  BMC Cancer       Date:  2010-05-05       Impact factor: 4.430

5.  MLH1 promoter hypermethylation: are you absolutely sure about the absence of MLH1 germline mutation? About a new case.

Authors:  Caroline Kientz; Fabienne Prieur; Alix Clemenson; Marie-Odile Joly; Marie-Laure Stachowicz; Jessie Auclair; Valéry Attignon; Renaud Schiappa; Qing Wang
Journal:  Fam Cancer       Date:  2019-11-19       Impact factor: 2.375

6.  MLH1 promotor hypermethylation does not rule out a diagnosis of Lynch syndrome: a case report.

Authors:  Victoria M Raymond; Arden M Morris; Khaled S Hafez; Joel K Greenson
Journal:  Fam Cancer       Date:  2015-03       Impact factor: 2.375

7.  Analysis of families with Lynch syndrome complicated by advanced serrated neoplasia: the importance of pathology review and pedigree analysis.

Authors:  Michael D Walsh; Daniel D Buchanan; Rhiannon Walters; Aedan Roberts; Sven Arnold; Diane McKeone; Mark Clendenning; Andrew R Ruszkiewicz; Mark A Jenkins; John L Hopper; Jack Goldblatt; Jillian George; Graeme K Suthers; Kerry Phillips; Graeme P Young; Finlay Macrae; Musa Drini; Michael O Woods; Susan Parry; Jeremy R Jass; Joanne P Young
Journal:  Fam Cancer       Date:  2009-02-25       Impact factor: 2.375

8.  Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.

Authors:  Anne M Mills; Sofia Liou; James M Ford; Jonathan S Berek; Reetesh K Pai; Teri A Longacre
Journal:  Am J Surg Pathol       Date:  2014-11       Impact factor: 6.394

9.  Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC).

Authors:  K Newton; N M Jorgensen; A J Wallace; D D Buchanan; F Lalloo; R F T McMahon; J Hill; D G Evans
Journal:  J Med Genet       Date:  2014-10-03       Impact factor: 6.318

10.  A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer.

Authors:  Marina Antelo; Francesc Balaguer; Jinru Shia; Yan Shen; Keun Hur; Leticia Moreira; Miriam Cuatrecasas; Luis Bujanda; Maria Dolores Giraldez; Masanobu Takahashi; Ana Cabanne; Mario Edmundo Barugel; Mildred Arnold; Enrique Luis Roca; Montserrat Andreu; Sergi Castellvi-Bel; Xavier Llor; Rodrigo Jover; Antoni Castells; C Richard Boland; Ajay Goel
Journal:  PLoS One       Date:  2012-09-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.